Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

(2020) Julie Crockett et al.   EPILEPSIA

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

(2020) Ian Miller et al.   JAMA Neurology

Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis

(2020) Simona Lattanzi et al.   EPILEPSIA

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

(2020) Orrin Devinsky et al.   ACTA NEUROLOGICA SCANDINAVICA

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

(2020) Philip N. Patsalos et al.   EPILEPSIA

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

(2020) Elizabeth A. Thiele et al.   JAMA Neurology

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

(2019) Elizabeth Thiele et al.   EPILEPSIA

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors

(2017) Cynthia Harden et al.   NEUROLOGY

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations

(2017) J. Helen Cross et al.   Frontiers in Neurology

Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment

(2016) Pavel Klein et al.   EPILEPSIA

Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study

(2016) Martin J. Brodie et al.   EPILEPSY RESEARCH

Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis

(2016) Jan Henje Döring et al.   PLoS One

Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies

(2015) David Ko et al.   EPILEPSY & BEHAVIOR

Definition and natural history of Lennox-Gastaut syndrome

(2011) Peter R. Camfield   EPILEPSIA

Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study

(2011) Elaine C. Wirrell et al.   EPILEPSY RESEARCH

Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome

(2011) Y. T. Ng et al.   NEUROLOGY

Adjunctive lamotrigine XR for primary generalized tonic–clonic seizures in a randomized, placebo-controlled study

(2010) Victor Biton et al.   EPILEPSY & BEHAVIOR

Clobazam in the treatment of Lennox-Gastaut syndrome

(2008) Joan A. Conry et al.   EPILEPSIA

Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology

(2008) Alexis Arzimanoglou et al.   LANCET NEUROLOGY

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

(2008) T. Glauser et al.   NEUROLOGY